Bildkälla: Stockfoto

Xspray Pharma Q3 2023: Approaching Commercialization - Redeye

Redeye makes minor changes to its fair value range following Xspray Pharma’s Q3 report, which contained no major surprises. We continue to observe a disconnect between operational newsflow and the share price as Xspray proceeds toward FDA approval and the anticipated Q3 2024 launch of Dasynoc.

Redeye makes minor changes to its fair value range following Xspray Pharma’s Q3 report, which contained no major surprises. We continue to observe a disconnect between operational newsflow and the share price as Xspray proceeds toward FDA approval and the anticipated Q3 2024 launch of Dasynoc.
Börsvärldens nyhetsbrev
ANNONSER